Mc Ilrath & Eck, LLC Editas Medicine, Inc. Transaction History
Mc Ilrath & Eck, LLC
- $572 Million
- Q4 2024
Shares
3 transactions
Others Institutions Holding EDIT
# of Institutions
225Shares Held
54.3MCall Options Held
412KPut Options Held
355K-
Black Rock Inc. New York, NY7.78MShares$12.1 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.82MShares$10.6 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny2.75MShares$4.29 Million0.0% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.16MShares$3.37 Million0.0% of portfolio
-
State Street Corp Boston, MA1.87MShares$2.92 Million0.0% of portfolio
About Editas Medicine, Inc.
- Ticker EDIT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 68,737,200
- Market Cap $107M
- Description
- Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...